Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
ppublish
Résumé
The early detection of prostate cancer (PCa) metastatic disease with PET imaging leads to stage migration and change of disease management. We aimed to assess the impact on clinical management deriving from prostate-specific membrane antigen (PSMA) imaging with a digital PET/CT during the routine application in the staging and restaging process of PCa. Eighty consecutive PCa patients underwent 18F-PSMA-1007. Digital PET/CT were retrospectively evaluated and discussed with oncologists to evaluate the impact on clinical management. Performances analysis, correlation among variables also considering semiquantitative parameters have been conducted. In the whole group of 80 patients at staging (N = 31) and restaging (N = 49), the detection rate of PSMA PET was 85% for all lesions. At staging, the performance analysis resulted in sensitivity 77.6%, specificity 89.5%, negative predictive value (NPV) 77.6%, positive predictive value (PPV) 89.5%, accuracy 85.7%, and area under curve (AUC) 0.87%. The performance of restaging PET in the group of patients with PSA values <1 ng/ml resulted in the following values: sensitivity 66.7%, specificity 92.9%, NPV 85.7%, PPV 81.3%, accuracy 82.6%, and AUC 0.79. Semiquantitative analysis revealed a mean value of SUVmax, metabolic tumor volume, and total lesion PSMA expression with differences in patients with high risk compared to low intermediate. At restaging PET, semiquantitative values of patients with total prostate specific antigen (tPSA) ≤ 1 ng/ml were significantly less than those of the tPSA > 1 ng/ml. A significant impact on clinical management was reported in 46/80 patients (57.5%) based on PSMA PET findings at staging and restaging. Although PSMA-PET provides optimal performances, its current role in redefining a better staging should be translated in the current clinical scenario about potential improvement in clinical/survival outcomes.
Identifiants
pubmed: 38835182
doi: 10.1097/MNM.0000000000001850
pii: 00006231-202407000-00009
doi:
Substances chimiques
Antigens, Surface
0
Glutamate Carboxypeptidase II
EC 3.4.17.21
FOLH1 protein, human
EC 3.4.17.21
PSMA-1007
0
Oligopeptides
0
Niacinamide
25X51I8RD4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-628Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. doi: 10.1002/ijc.33588.
American Cancer Society. Cancer facts & figures 2021. American Cancer Society; 2021.
Shoag J, Barbieri CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl 2016; 18:543–548.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79:243–262.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2023; 21:1067–1096.
Mogensen AW, Petersen LJ, Torp-Pedersen C, Nørgaard M, Pank MT, Zacho HD. Use of 18F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study. BMJ Open 2022; 12:e058898.
Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The evolving role of prostate-specific membrane antigen-based diagnostics and therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book 2019; 39:321–330.
Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2:1445–1451.
Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48:326–334.
Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol 2018; 8:623.
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017; 44:678–688.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395:1208–1216.
Olivier P, Giraudet AL, Skanjeti A, Merlin C, Weinmann P, Rudolph I, et al. Phase III study of 18F-PSMA-1007 versus 18F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study. J Nucl Med 2023; 64:579–585.
Mazzola R, Cuccia F, Pastorello E, Salgarello M, Francolini G, Livi L, et al. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. Clin Exp Metastasis 2022; 39:443–448.
Zhou J, Gou Z, Wu R, Yuan Y, Yu G, Zhao Y. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal Radiol 2019; 48:1915–1924.
Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol 2019; 11:1758835919876828.
Bauckneht M, Checcucci E, Cisero E, Rizzo A, Racca M, De Cillis S, et al. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur J Nucl Med Mol Imaging 2023; 51:864–870.
Lorusso V, Talso M, Palmisano F, Branger N, Granata AM, Fiori C, et al. Is imaging accurate enough to detect index lesion in prostate cancer? Analysis of the performance of MRI and other imaging modalities. Minerva Urol Nephrol 2023; 76:22–30.
Maiorano BA, De Giorgi U, Roviello G, Messina C, Altavilla A, Cattrini C, et al. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. ESMO Open 2022; 7:100575.
Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, et al. Surveillance or metastasis-directed Therapy for OligoMetastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer 2014; 14:671.
Alongi P, Laudicella R, Lanzafame H, Farolfi A, Mapelli P, Picchio M, et al. PSMA and choline PET for the assessment of response to therapy and survival outcomes in prostate cancer patients: a systematic review from the literature. Cancers (Basel) 2022; 14:1770.
Cattrini C, Caffo O, De Giorgi U, Mennitto A, Gennari A, Olmos D, et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers (Basel) 2022; 14:1792.
Zukotynski KA, Emmenegger U, Hotte S, Kapoor A, Fu W, Blackford AL, et al. Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide. J Nucl Med 2021; 62:1430–1437.
Alongi P, Stefano A, Comelli A, Laudicella R, Scalisi S, Arnone G, et al. Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients. Eur Radiol 2021; 31:4595–4605.
Evangelista L, Alongi P. PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer? Eur J Nucl Med Mol Imaging 2021; 48:1709–1711.
Plouznikoff N, Artigas C, Sideris S, Martinez Chanza N, Gil T, Peltier A, et al. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med 2019; 33:945–954.
Demirci E, Kabasakal L, Şahin OE, Akgün E, Gültekin MH, Doğanca T, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict clinically significant prostate cancer? Nucl Med Commun 2019; 40:86–91.
Ali H, Rashid-Ul-Amin S, Hai A. Standardised uptake value in organ confined prostate cancer in 68-Ga-prostate-specific membrane antigen positron emission tomography-computed tomography scan and its correlation with prostate specific antigen level and Gleason score. J Cancer Allied Spec 2023; 9:529.
Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med 2016; 57:563–567.
Vlachostergios PJ, Niaz MJ, Sun M, Mosallaie SA, Thomas C, Christos PJ, et al. Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer. Front Oncol 2021; 11:630589.
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol 2019; 76:469–478.
Nagaya N, Nagata M, Lu Y, Kanayama M, Hou Q, Hotta Z-U, et al. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS One 2020; 15:e0226219.
Ambrosini F, Falkenbach F, Budaeus L, Graefen M, Koehler D, Lischewski F, et al. Prevalence of bilateral loco-regional spread in unilateral pelvic PSMA PET positive recurrent prostate cancer. Minerva Urol Nephrol. 2023; 75:734–742.
Garje R, Rumble RB, Parikh RA. Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO rapid recommendation. J Clin Oncol 2022; 40:3664–3666.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. VISION investigators. lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385:1091–1103.
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer 2023; 185:178–215.